Published: Mar, 2017
The global market for non-alcoholic steatohepatitis (NASH) biomarkers features a highly competitive vendor landscape, with leading companies capturing sizeable share in the global market owing to their patented markers, observes Transparency Market Research in a recent report. As the treatment cycle of NASH is long, routine monitoring regarding the progress of the treatment is crucial, demanding use of methods such as liver biopsies.
However, the vast limitations associated with liver biopsy in NASH patients have compelled companies in the market to develop non-invasive diagnostic methods for NASH monitoring. Additionally, collaborations of biomarker-based diagnostic tool providers with companies capable of validating the accuracy and efficacy of diagnostic tools during clinical trials is a popular trend in the market. Transparency Market Research states that the global NASH biomarkers market will exhibit an impressive 31.7% CAGR over the period between 2016 and 2024, reaching a valuation of US$1.7 bn by 2024 from US$201.2 mn in 2016.
Europe Market to Retain Dominance throughout Forecast Period
Of the key types of biomarkers available in the global market, including serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, and oxidative stress biomarkers, the segment of serum biomarkers has achieved significant popularity among healthcare practitioners over the years. The segment dominated the global market in 2015, accounting for the leading share in terms of revenue contribution. Over the report’s forecast period, however, the segment of hepatic fibrosis biomarkers will lead in terms of prospective rate of growth, at nearly 38% CAGR. The overall demand for hepatic fibrosis biomarkers will benefit from the increased realization regarding their high efficacy and accuracy.
In terms of geography, the Europe market accounted for over 50% of the global market in 2015, followed by North America. Europe is expected to retain dominance in the market in the near future as well, exhibiting a remarkable 30.8% CAGR from 2016 through 2024. North America is also expected to continue to hold a significant share in the global market owing to the established NASH healthcare sector in the region.
Rising Prevalence of Non-alcoholic Liver Diseases to Increase Focus of Healthcare Sector on NASH Treatment Options
The significant rise in the rate of incidence of non-alcoholic liver diseases across the globe is the key factor to have increased the magnitude of research and development activities in the field of non-alcoholic steatohepatitis biomarkers in the past few years. Over the next few years, the vast patient pool of type 2 diabetes, which is more prone to liver conditions such as non-alcoholic fatty liver disease (NAFLD), will emerge as a key factor driving the NASH biomarkers market. Other factors, including the rising air pollution, sedentary lifestyles, and unhealthy eating habits will also drive the global NASH biomarkers market in the near future.
Limitations in Accuracy of Presently Marketed Biomarkers Restrict Market’s Growth Prospects
Most of the NASH biomarkers and panels used by researchers and healthcare practitioners fail to present results with high accuracy and sensitivity. As observed in received operating characteristic analysis, the accuracy of most biomarker panels available in the market is around 0.80 - a factor that could hinder the overall growth prospects of the market by compelling consumers to prefer alternative therapeutic and diagnostic solutions for managing NASH. Moreover, the fact that diagnostic results produced by some NASH diagnostic markers overlap with disease indicators for other metabolic diseases, such as diabetic hepatosclerosis and glycogenic hepatopathy, questions the reliability of the available NASH diagnostic biomarkers in the global market.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Non-alcoholic Steatohepatitis (NASH) Biomarkers Market (Marker Type - Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, and Oxidative Stress Biomarkers; End User - Contract Research Organizations (CRO) and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
For the report, the market has been segmented as follows:
Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Marker Type
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by End-User
- Contract Research Organization(CRO) & Pharmaceutical Industry
- Academic Research Institutes
- Diagnostic Laboratories
Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Geography
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453